months in a group of nearly 1200 patients with early stage alzheimer s, the best results reported so far. but there were some serious side effects. at least two volunteers died as a result of brain swelling. now, in november, another antibody treatment, called lecanemab, was the first drug ever to show it could slow the progress of alzheimer s disease. dementia researchers say we re now entering a new era where alzheimer s is treatable. we really see that we re at a revolutionary point in how we treat alzheimer s disease. so what we now need, when we have the full results, is for the regulators to make quick decisions so that patients that could benefit from these treatments are able to benefit. now we don t know how much donanemab will cost, but lecanemab is over £20,000 a year per patient in the us, where it s already licensed. dementia specialists say we ll need a complete overhaul of alzheimer s services here, including access to specialist brain scans if patients are to